J. R. Infante

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Phase I/ii Study, Mut Braf Melanoma, Immunotherapeutics +20

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 132 citations · Full text

Pancreatic Cancer, Medicine, Pharmacology +6

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

J. R. Infante, G. S. Falchook, Donald P. Lawrence et al. · Journal of Clinical Oncology · 2011 · 122 citations

Brafi Exposure, Phase I/ii Study, Immunology +19

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

J. R. Infante, Leslie A. Fecher, Sujatha Nallapareddy et al. · Journal of Clinical Oncology · 2010 · 121 citations

Pathology, Pharmacotherapy, Tumor Biology +21

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

H. Burris, Jordi Rodón, Shaleekha Sharma et al. · Journal of Clinical Oncology · 2010 · 109 citations

Chemoprevention Strategy, First-in-human Phase, Pathology +17